Back to News
Market Impact: 0.22
Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Norovirus Study
Source: Nasdaq
Healthcare & Biotech
Cocrystal Pharma (COCP) announced that it dosed the final participant in its Phase 1b human challenge study of CDI-988 for norovirus prevention and treatment. Completion of dosing is a positive clinical-development milestone, but no efficacy, safety, or financial results were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
COCP0.45
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine